A decade after the passage of RA 10747, commonly known as the Rare Disease Act, gaps in implementation continue to affect patients living with rare diseases. Health experts warn that without sustained government funding and stronger implementation, patients may continue to face delays in diagnosis, limited access to specialized treatment, and negative and potentially irreversible impacts on their health outcomes and quality of life.
In 2016, the Rare Disease Act was passed to provide support, access to care, and treatment to afflicted patients and their families. However, delivering the law’s full promise is hindered by the lack of sustained government investment and coordinated action across the healthcare system.[1]
Following the approval of the law’s implementing rules and regulations (IRR), the Department of Health’s Rare Disease Technical Working Group first worked on the Integrated Rare Diseases Management Program (IRDMP). The program sets out how government agencies, hospitals, specialists, and patient groups should work together to diagnose, treat, and support Filipinos with rare diseases. Its 2022–2026 strategic plan guides the government’s investments in rare disease care and ends this year, making the law’s 10th year a crucial moment to review its progress and plan the next phase.
“A decade after the law was passed, the challenge remains in ensuring that the support it promised reaches the patients who need it,” said Dr. Ebner Bon Maceda, Director of the Institute of Human Genetics (IHG) at the National Institutes of Health (NIH), at the University of the Philippines (UP) Manila. “Patients continue to face limited access to specialists and appropriate treatment, navigate a complex healthcare system, and shoulder a significant portion of the financial burden of managing their conditions.”
Rare diseases, by definition, affect a small fraction of the population. According to the World Health Organization (WHO), a rare disease typically affects one in 2,000 people or less.[2] In the Philippines, a condition is considered a rare disease if it affects 1 in 20,000 individuals.[3] Approximately 6% of the population is affected by a rare disease. [4] In the Philippines, there are currently 159 recognized rare diseases.
Because these conditions are uncommon, rare disease patients may require access to highly specialized professionals or undergo extensive diagnostic testing to receive an accurate diagnosis. Some may even need lifelong monitoring, rehabilitation, and medicines specifically developed for their conditions.
“The challenges faced by rare disease patients make the implementation of the Rare Disease Act particularly important,” stressed Dr. Maceda. “Legislation alone cannot guarantee that the specialized services are consistently available for patients. They need functioning referral systems, trained healthcare professionals, accessible diagnostic facilities, and sustained funding to ensure that the law’s provisions translate to actual care.”
For instance, a child may begin exhibiting symptoms as early as three years old, prompting the family to consult at least four doctors and several specialists in search of an accurate diagnosis. Despite years of consultations and medical evaluations, the family may eventually learn that the child has a rare disease with no available treatment. Some rely on charitable programs to have access to treatment, and even these cannot cover every patient living with a rare disease. Experiences such as these highlight the long and difficult diagnostic journey many rare disease patients endure, as well as the emotional and financial toll on families who must navigate a healthcare system with limited specialized services and treatment options.
A 2020 study by the IHG at the UP Manila identified 567 patients with inherited metabolic diseases in its registry between 1999 and 2016, with 14.8% having lysosomal storage disorders such as mucopolysaccharidosis (MPS), Gaucher disease, Pompe disease, and Fabry disease. The study highlighted the serious consequences of delayed diagnosis, with 80.6% of patients with Maple Syrup Urine Disease (MSUD) and 94.7% of those with MPS experiencing developmental delays or intellectual disability. These findings underscore the urgent need for early diagnosis, access to specialized care, and greater availability and affordability of enzyme replacement therapy (ERT) for eligible patients with lysosomal storage disorders to help manage disease progression and improve quality of life. 5
As the Rare Disease Act marks its 10th year, the Philippine Health Insurance Corporation (PhilHealth) plans to release its rare disease benefit packages before the end of the year.
For Juan Magdaraog, a patient advocate from the Philippine Society for Orphan Disorders (PSOD), these benefit packages are a welcome step toward improving the quality of life of rare disease patients. “For many families, the cost of care forces painful choices between treatment and everyday needs. Financial support for their care can lift part of that weight and allow families to focus on looking after their loved ones,” Madaraog said.
“But for rare disease patients, time is never on their side,” Madaraog added. “Many of these conditions get worse over time, and every month spent waiting for a diagnosis or treatment can cause damage that can no longer be undone. Getting the right care early can mean the difference between a child who grows up, goes to school, and lives a full life, and one who loses that chance.”
“That is why these benefits must reach patients without delay. With the Integrated Rare Diseases Management Program’s strategic plan ending this year, now is the time to build on what it has started and strengthen it for the years ahead,” asserted Madaraog. “A working rare disease registry will help find, diagnose, and treat patients sooner. We must also listen to the perspectives of patient organizations, whose experiences can guide policies toward what patients and families truly need.”
Ultimately, Dr. Maceda and PSOD agree that strengthening the implementation of the Rare Disease Act is about ensuring that the rarity of a condition does not diminish a patient’s access to specialized care. Sustained government funding, commitment, and stronger collaboration among stakeholders bring Filipinos afflicted with rare diseases closer to the timely, appropriate, and equitable care that they deserve.


